Prenetics Ltd Stock Price, News & Analysis

Prenetics (NASDAQ: PRE) will participate in two investor conferences in December 2025: The Benchmark Company's 14th Annual Discovery One-on-One Conference on December 4, 2025 at the New York Athletic Club in New York City, and Sidoti’s Year End Virtual Investor Conference on December 10-11, 2025. CEO Danny Yeung will be available for one-on-one meetings at the Benchmark event and will deliver a formal presentation at 10:00 a.m. ET on December 10, 2025 at the Sidoti conference. CFO Stephen Lo will join for one-on-one meetings. A replay of the Sidoti presentation webcast will be available on the company’s investor relations website. For one-on-one meeting requests, contact Investor Relations at PRE@mzgroup.us or your Benchmark/Sidoti representative.

Prenetics (NASDAQ: PRE) executives executed open-market purchases totaling 111,911 shares for approx. $1,446,887 during the company’s trading window from Nov 12–21, 2025. Key buys: CEO Danny Yeung purchased 40,118 shares (~$502,000) on Nov 18–19; CMO Rahul Ramchand bought 60,000 shares (~$793,972) on Nov 12–14; CFO Stephen Lo bought 8,000 shares (~$100,915) on Nov 21; President Americas David Vanderveen bought 3,793 shares (~$50,000) on Nov 20. The company said these purchases reflect executive conviction in Prenetics and IM8 and will be furnished as an exhibit to a Form 6-K filed with the SEC.

Prenetics (NASDAQ: PRE) received an Overweight reiteration from Cantor Fitzgerald with a revised 12‑month price target of $31 on Nov 11, 2025. Cantor highlighted IM8 performance: 3Q25 revenue $23.6M (≈568% YoY) and IM8 revenue $17.2M (≈76% sequential) with ~60% gross margins and a ~3.9‑month customer payback.

Cantor cites ~$120M total liquidity including ~387 BTC (~$41M), and forecasts FY2026 revenue ≈ $217M. The $31 target reflects model adjustments for a planned Europa divestment; Cantor still views PRE as undervalued at ~0.7× EV/2026E revenue versus ~1.1× peers.

Prenetics (NASDAQ: PRE) reported record Q3 2025 results with total revenue $23.6M (+568% YoY) and IM8 driving growth: Q3 IM8 revenue $17.2M, October monthly revenue ~$9.0M and IM8 on track for $120M ARR by Dec 2025. IM8 metrics: ~60% gross margin, ~80% subscription rate, $150 AOV, and 3.9 months payback. Company holds ~387 BTC (~$41M) and ~$82M cash, ~$120M total liquidity. Prenetics completed a $44M equity offering and reaffirmed FY2026 IM8 revenue guidance of $180–$200M (targeting ~$300M ARR by end-2026).

Prenetics (NASDAQ: PRE) will release third quarter 2025 financial results for the period ended September 30, 2025 before market open on Monday, November 10, 2025. The company will hold its inaugural earnings conference call the same day at 8:30 a.m. Eastern Time to discuss results and answer analyst questions.

Dial-in details: 1-844-425-9470 (U.S.) and 201-298-0878 (international). A live webcast will be available on the PRE conference call page and an audio replay will be posted on the investor relations website at https://ir.prenetics.com/.

Prenetics (Nasdaq: PRE) announced that its IM8 brand achieved a record $9.0 million in revenue for October 2025, representing 32% month-over-month growth from September's $6.8 million, and reached approximately $108 million in annualized recurring revenue (ARR) 11 months after launch.

Other disclosed metrics: an all-time single-day revenue record of $400,000, average order value rising from ~$110 to $145, 13 million servings delivered to over 420,000 customers across 31 countries, and 80% of new orders via subscription. Prenetics completed a $44 million equity offering to fund global expansion and projects a minimum of $10 million monthly revenue by December 2025, ~$60 million in IM8 revenue for FY2025, and $180–200 million for FY2026.

Prenetics (NASDAQ: PRE) acquired 100 Bitcoin at an average price of $109,594 per BTC, increasing its treasury to 378 BTC (valued at ~$46 million). The purchase was funded as the initial deployment of proceeds from a completed $44 million equity offering that closed on October 28, 2025.

Following the acquisition and financing, Prenetics reports approximately $127 million in total liquidity ($86 million cash and $41 million in Bitcoin) and zero debt. The company also says its IM8 supplement brand reached $100 million ARR within 11 months, with 420,000 customers, ~80% subscription reorder rate, and FY2026 IM8 revenue guidance of $180–$200 million.

Prenetics (NASDAQ: PRE) published a 32-page manifesto titled “The Dual-Engine Revolution” by CEO Danny Yeung outlining a strategy that pairs rapid healthcare growth with a disciplined Bitcoin treasury approach.

Key facts: IM8 reached $100M ARR in 11 months and projects $180–$200M revenue for FY2026. The company holds 277 BTC and adds 1 BTC daily via a stated accumulation strategy. The manifesto is available in multiple formats and links to investor resources and real-time BTC holdings.

Prenetics (NASDAQ: PRE) closed a best-efforts public offering on Oct 28, 2025, selling 2,722,642 Class A ordinary shares and associated Class A and Class B common warrants at a combined price of $16.08 per share with warrants. Gross proceeds were approximately $44.0 million before fees, down from ~$48.0 million previously announced. The Class A warrants carry a $24.12 exercise price (50% premium) and Class B warrants a $32.16 exercise price (100% premium); both are immediately exercisable for five years. The company said proceeds will fund the global expansion of IM8 and strategic accumulation of Bitcoin (BTC). Dominari Securities acted as sole placement agent.